Samil Pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 01:58 am
Share
Samil Pharmaceutical Co.,Ltd reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 1,070.32 million compared to KRW 549.42 million a year ago. Net loss was KRW 1,920.48 million compared to KRW 1,671.46 million a year ago. Basic loss per share from continuing operations was KRW 138.1818 compared to KRW 120 a year ago. Diluted loss per share from continuing operations was KRW 138.1818 compared to KRW 120 a year ago. Basic loss per share was KRW 138.1818 compared to KRW 120 a year ago.
For the nine months, sales was KRW 2,960.54 million compared to KRW 1,476.95 million a year ago. Net loss was KRW 1,858.78 million compared to KRW 2,216.3 million a year ago. Basic loss per share from continuing operations was KRW 134.5455 compared to KRW 160.9091 a year ago. Diluted loss per share from continuing operations was KRW 134.5455 compared to KRW 160.9091 a year ago. Basic loss per share was KRW 134.5455 compared to KRW 160.9091 a year ago.
SAMIL PHARMACEUTICAL CO., LTD is a Korea-based company mainly engaged in the manufacture of medicines. The Companyâs products portfolio consists of gastro-intestinal drugs such as antiulcerants, gastroprokinetic agents, digestive enzymes with nutrients and laxatives under the brand names of Plybutine, Gliptide and others; antipyretic, analgesic and anti-inflammatory agents under the brand name Brufen; nutritional supplements such as vitamins, minerals and immunosuppressants, and others including antigout agents, anti-parkinsonism agents and others. In addition, it is engaged in the provision of miscellaneous goods. The Company distributes its products within domestic market and to overseas markets. On November 29, 2013, it transferred its entire shares of a Korea-based company, which is engaged in the sale of medical products.